Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 1/2017

01-01-2017 | Letter to the Editor

Endobarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism

Authors: Radwan Kassir, Jean Gugenheim, Tarek Debs, Imed Ben Amor, Olivier TIffet

Published in: Obesity Surgery | Issue 1/2017

Login to get access

Excerpt

The EndoBarrier®, also known as a duodenal-jejunal bypass sleeve or a gastrointestinal liner, is a single-use 60-cm impermeable fluoropolymer sleeve that is placed endoscopically via the mouth and anchored in the first part of the small bowel (duodenum) in a procedure that takes around 30 min. EndoBarrier® receives the contents of the stomach and acts to reduce the uptake of nutrients and calories from the first part of the small bowel (the duodenum and the first section of the jejunum). EndoBarrier® is the first endoscopically delivered device for people living with uncontrolled type 2 diabetes (T2DM) and obesity. …
Literature
1.
Vilarrasa N, de Gordejuela AG, Casajoana A, et al. Endobarrier® in grade I obese patients with long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism. Obes Surg. 2016.
2.
Muñoz R, Dominguez A, Muñoz F, et al. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients. Surg Endosc. 2014;28(4):1056–62.CrossRefPubMed
3.
de Jonge C, Rensen SS, D'Agnolo HM, et al. Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetes. Obes Surg. 2014;24(2):337–41.CrossRefPubMed
Metadata
Title
Endobarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism
Authors
Radwan Kassir
Jean Gugenheim
Tarek Debs
Imed Ben Amor
Olivier TIffet
Publication date
01-01-2017
Publisher
Springer US
Published in
Obesity Surgery / Issue 1/2017
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2406-7

Other articles of this Issue 1/2017

Obesity Surgery 1/2017 Go to the issue

Original Contributions

Influence of Liver Disease on Perioperative Outcome After Bariatric Surgery in a Northern German Cohort

Original Contributions

Long-Term Results of Laparoscopic Sleeve Gastrectomy for Morbid Obesity: 5 to 8-Year Results

Original Contributions

A New Concept in Bariatric Surgery. Single Anastomosis Gastro-Ileal (SAGI): Technical Details and Preliminary Results

Original Contributions

Conversion to Gastric Bypass After Either Failed Gastric Band or Failed Sleeve Gastrectomy

Original Contributions

Determinants of Evolution of Glomerular Filtration Rate After Bariatric Surgery: a 1-Year Observational Study

Review Article

Different Supplementation Regimes to Treat Perioperative Vitamin B12 Deficiencies in Bariatric Surgery: a Systematic Review